Skip to content

Chitosan oligosaccharides show protective effects in coronary heart disease by improving antioxidant capacity via the increase in intestinal probiotics

Chitosan oligonucleotides and coronary heart disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020902
Enrollment
Unknown
Registered
2019-01-22
Start date
2018-12-05
Completion date
Unknown
Last updated
2019-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease

Interventions

COG and CG:oral adiminstrated with COS

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The patients had clinical manifestations of typical pain, which was mostly occurred in the early morning. Sudden and severe stern post-sternal or precordial compression pain could be found but the cause was not obvious. Taking a rest or taking nitroglycerin tablets could not alleviate the symptoms. The patients were often upset, sweating, fearful, chest tight or had a sense of death. Typical electrocardiogram showed that ST-segment elevation was arch-back-up with wide and deep Q wave (pathological Q wave) and T wave inversion. The levels of serum myocardial necrosis markers: myoglobin, troponin I (cTnI) or myocardial markers such as cardiac troponin T (cTnT) and creatine kinase isoenzyme CK-MB were significantly elevated.

Exclusion criteria

Exclusion criteria: (1) gastrointestinal diseases, such as gastritis, gastric ulcer, etc., and diarrhea in the past 4 weeks, or a history of gastrointestinal surgery; (2) combined symptoms of heart failure; (3) cardiogenic shock; (4) previous coronary revascularization procedures (e.g., thrombolysis and PCI); (5) combined symptoms with autoimmune diseases; (6) other endocrine diseases such as thyroid; (7) serious damage to organs such as liver and kidney; (8) oral and intravenous antibiotics administration for nearly 1 week, and adjustment of intestinal flora preparation and gastric mucosal protective agent for nearly 1 week; (9) hypertension, obesity, diabetes, and dyslipidemia; (10) pregnant.

Design outcomes

Primary

MeasureTime frame
GOS;

Countries

China

Contacts

Public ContactJiang Tiechao

China-Japan Union Hospital of Jilin University

jiangtc@jlu.edu.com+86 18943679002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026